Atrion Corp (ATRI, Financial)(30-Year Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2019. Atrion Corp supplies medical devices and related components. The company makes various products such as fluid delivery devices and sells it worldwide. It aims to serve the patients with heart disease and eye problems. Atrion Corp has a market cap of $1.22 billion; its shares were traded at around $657.40 with a P/E ratio of 33.33 and P/S ratio of 7.86. The dividend yield of Atrion Corp stocks is 0.89%. Atrion Corp had annual average EBITDA growth of 6.30% over the past ten years. GuruFocus rated Atrion Corp the business predictability rank of 4.5-star. GuruFocus has detected 1 severe warning sign with Atrion Corp. .
For the last quarter Atrion Corp reported a revenue of $34.5 million, compared with the revenue of $34.93 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $155.1 million, an increase of 1.7% from last year. For the complete 30-year financial data, please go here.. For the last five years Atrion Corp had an average revenue growth rate of 1.9% a year.
The reported diluted earnings per share was $19.73 for the year, an increase of 7% from previous year. Over the last five years Atrion Corp had an EPS growth rate of 7.4% a year. The Atrion Corp had a decent operating margin of 26.14%, compared with the operating margin of 27.36% a year before. The 10-year historical median operating margin of Atrion Corp is 28.39%. The profitability rank of the company is 9 (out of 10).
At the end of the fiscal year, Atrion Corp has the cash and cash equivalents of $45.0 million, compared with $58.8 million in the previous year. The company had no long term debt. The interest coverage to the debt is 3.8. Atrion Corp has a financial strength rank of 9 (out of 10).
At the current stock price of $657.40, Atrion Corp is traded at close to its historical median P/S valuation band of $677.03. The P/S ratio of the stock is 7.86, while the historical median P/S ratio is 4.56. The intrinsic value of the stock is $271.02 a share, according to GuruFocus DCF Calculator. The stock lost 20.89% during the past 12 months.
For the complete 20-year historical financial data of ATRI, click here.
